InspireMD Inc. (NSPR)
Summary
NSPR Chart
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
InspireMD Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Christopher C. Powers Farther Finance Advisors, LLC | 1,000 | $2,440 | $701.6 | -$1,738.4 | -71.25% |
 VESTIA PERSONAL WEALTH ADVISORS VESTIA PERSONAL WEALTH ADVISORS | 24,425 | $58,864.11 | $17,586 | -$41,278.11 | -70.12% |
InspireMD Inc. (NSPR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has InspireMD Inc. ever had a stock split?
InspireMD Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Marvin L. Slosman CEO | NASDAQ (CM) Exchange | 45779A846 CUSIP |
| IL Country | 127 Employees | - Last Dividend | 1 Oct 2015 Last Split | 12 Apr 2011 IPO Date |
Overview
InspireMD, Inc. is a pioneering medical device company focused on the innovation and commercialization of its proprietary MicroNet stent platform technology. This technology is specifically designed to address the needs of patients suffering from vascular and coronary diseases. The company’s operations span across a variety of global regions, including Europe, Latin America, the Middle East, and the Asia Pacific. By forging strategic agreements and collaborations, such as the one with the Jacobs Institute for a feasibility study on the CGuard Prime for acute stroke patients, InspireMD, Inc. continues to broaden its research and deployment horizon. Founded in 2005, the company has established its headquarters in Tel Aviv-Yafo, Israel, marking its commitment to innovation in the field of medical technology. InspireMD, Inc. leverages local distribution partners to make its products accessible to a wide array of healthcare professionals and patients, underscoring its mission to enhance patient care and outcomes in the segments it serves.
Products and Services
- CGuard Carotid Embolic Prevention System (EPS):
- CGuard Prime Stent System:
- SwitchGuard NPS:
- Treating Acute Stroke with Tandem Lesions:
This system is tailored for carotid artery applications. It represents a significant advancement in the prevention of stroke-causing emboli, showcasing the company’s commitment to combating cardiovascular diseases through innovative technology.
A mesh-covered self-expanding carotid stent, the CGuard Prime represents the next generation in the company's product offering. This system is designed to provide an even higher level of protection against the risks associated with carotid artery stenting, marking a milestone in the field of vascular intervention.
This non-invasive transcarotid artery revascularization device is a testament to InspireMD, Inc.'s dedication to less invasive treatment options. The SwitchGuard NPS aims to offer a safer and more effective alternative for patients undergoing revascularization procedures, especially those at high risk or with challenging anatomies.
InspireMD, Inc. is also exploring treatments for acute stroke, specifically targeting patients with tandem lesions. This innovative approach underscores the company’s broader vision to address complex vascular diseases with forward-thinking solutions.
